Clik here to view.
BeiGene Enters Next Phase of Global Growth with Announcement of Second...
SAN MATEO, Calif. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the second quarter 2024 and corporate updates that strengthen the...
View ArticleClik here to view.
Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer;...
TOKYO Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical...
View ArticleClik here to view.
Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment...
TOKYO Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases,...
View ArticleClik here to view.
ベイジーン、2024年第2四半期決算および事業に関する最新情報を発表し、グローバル成長の次なる段階へ
カリフォルニア州、サンマテオ （ビジネスワイヤ） — がん領域専門のグローバル製薬企業であるベイジーン（NASDAQ：BGNE；HKEX：06160；SSE：688235)は、2024年第2・四半期の業績および将来のグローバル成長を強化する事業の最新情報を発表しました。...
View ArticleClik here to view.
Nichi BRITE β-葡聚糖作为辅助胰腺癌治疗的营养补充剂；日本近森医院报告了令人鼓舞的临床结果
东京 (美国商业资讯)– 服用Nichi BRITE β-葡聚糖可提高免疫力，进而降低接受恶性胰腺肿瘤手术切除患者的胰腺癌生物标志物及其复发率，这一发现在日本横滨举行的ASCO® Breakthrough会议上进行了呈报。在胃肠外科医生和日本高知县近森医院营养支持小组的研究中，与对照组相比，给药Nichi...
View ArticleClik here to view.
Clik here to view.
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy,...
MIAMI Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the primary analysis of the Phase III HARMONi-2 trial featuring its novel, potential...
View ArticleClik here to view.
Inocras to Offer High Quality and Cost-Effective Whole Genome Sequencing and...
SAN DIEGO Inocras Inc., a leader in whole genome sequencing and bioinformatics, announced today that it is now offering whole genome sequencing services using the UG 100TM sequencer from Ultima...
View ArticleClik here to view.
ALAFIA Unveils AIVAS Interactive Supercomputer, an All-in-One Interactive...
GAINESVILLE, Fla. Alafia Ai, Inc. (“ALAFIA”), announces the general availability of AIVAS, an all-in-one interactive high-performance personal supercomputer designed to revolutionize the development...
View ArticleClik here to view.
ヒストソニックス、非侵襲的なヒストトリプシー・プラットフォームの立ち上げ拡大に向けた1億200万ドルのシリーズD資金調達を発表
ミネアポリス （ビジネスワイヤ） — ヒストソニックスは、Edison®ヒストトリプシーシステムのメーカーであり、画期的なヒストトリプシー療法のプラットフォームです。このたびヒストソニックスは、1億200万ドルのシリーズD資金調達を完了したことを発表しました。本ラウンドは、成長段階の投資で世界をリードするアルファ・ウェーブ・ベンチャーズによって主導されており、新規投資家であるAmzak...
View ArticleClik here to view.
HistoSonics宣布获得超额认购的1.02亿美元D轮融资，以推进非侵入性组织摧毁术平台的推出
明尼阿波利斯 (美国商业资讯)– HistoSonics是Edison®组织摧毁术系统和新型组织摧毁术疗法平台的制造商。该公司今天宣布完成超额认购的1.02亿美元D轮融资。本轮融资由全球领先的成长期投资机构Alpha Wave Ventures领投，新投资者Amzak Health和HealthQuest Capital以及现有投资者Johnson & Johnson...
View ArticleClik here to view.
U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New...
OSAKA, Japan & WALTHAM, Mass. Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the U.S. Food and Drug Administration (FDA)...
View ArticleClik here to view.
ENHERTU® Type II Variation Application Validated by EMA for Patients with...
TOKYO & MUNICH Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxtecan) as a...
View ArticleClik here to view.
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain...
TOKYO & BASKING RIDGE, N.J. ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of unresectable or metastatic hormone...
View ArticleClik here to view.
InnoCare Releases 2024 Interim Results and Business Highlights
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 interim results and corporate update as...
View ArticleClik here to view.
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the...
SEOUL, South Korea Innovo Therapeutics Inc. has announced the results of its Phase 2 clinical trial demonstrating the innovative efficacy of INV-001 in scar treatment. The trial involved 77 Korean...
View ArticleClik here to view.
イノボ・セラピューティクス、甲状腺摘出術後の瘢痕に対するINV-001の革新的な有効性を示す第2相臨床試験結果を発表
韓国ソウル （ビジネスワイヤ） — イノボ・セラピューティクス（Innovo Therapeutics Inc.）は、瘢痕治療におけるINV-001の革新的な有効性を実証する第2相臨床試験の結果を発表しました。...
View ArticleClik here to view.
Innovo Therapeutics公司公布第二期临床试验结果，证实INV-001在治疗甲状腺切除术后疤痕方面具有创新疗效
韩国首尔 (美国商业资讯)– Innovo Therapeutics Inc.公布了第二期临床试验结果，证实了INV-001在治疗疤痕方面具有创新疗效。...
View ArticleClik here to view.
Zai Lab Announces Participation in September Investor Conferences
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences...
View ArticleClik here to view.
ALAFIA、医療分野における人工知能ソフトウェアアプリケーションのためのオールインワンのインタラクティブな高性能パーソナルスーパーコンピュータAIVASを発表
フロリダ州ゲインズビル （ビジネスワイヤ） — Alafia Ai, Inc....
View Article